Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: A substudy of TALENT

Colomba Falcone, Maria Paola Buzzi, Sara Bozzini, Chiara Boiocchi, Angela D'Angelo, Sandra Schirinzi, Ciro Esposito, Massimo Torreggiani, Jasmine Choi, Michael Ochan Kilama, Giuseppe Mancia

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Some antihypertensive drugs have also renoprotective and anti-inflammatory properties that go beyond their effect on blood pressure. It has been suggested that microalbuminuria and glomerular filtration rate (GFR) are associated with circulating levels of the soluble form of the receptor, sRAGE (soluble receptor for advanced glycation ends-products). In the present analysis, we used data from the TALENT study to evaluate soluble receptor for advanced glycation end-products (sRAGE) plasma levels in patients with hypertension and high-cardiovascular risk-treated nifedipine and telmisartan in combination. Treatment with nifedipine-telmisartan significantly decreased mean systolic and diastolic ambulatory blood pressure and resulted in a significant increase in sRAGE plasma concentrations after 24 weeks of therapy. We concluded that in hypertensive patients with early-stage renal disease, sRAGE concentrations are not influenced by either microalbuminuria or GFR. Long-term treatment with a combination of nifedipine-telmisartan may have a beneficial effect increasing sRAGE plasma levels, thus exerting an atheroprotective and anti-inflammatory activity.

Original languageEnglish
Article number874149
JournalMediators of Inflammation
Volume2012
DOIs
Publication statusPublished - 2012

Fingerprint

Nifedipine
Glomerular Filtration Rate
Anti-Inflammatory Agents
Blood Pressure
Therapeutics
Antihypertensive Agents
Advanced Glycosylation End Product-Specific Receptor
telmisartan
Hypertension
Kidney

ASJC Scopus subject areas

  • Immunology
  • Cell Biology

Cite this

Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment : A substudy of TALENT. / Falcone, Colomba; Buzzi, Maria Paola; Bozzini, Sara; Boiocchi, Chiara; D'Angelo, Angela; Schirinzi, Sandra; Esposito, Ciro; Torreggiani, Massimo; Choi, Jasmine; Ochan Kilama, Michael; Mancia, Giuseppe.

In: Mediators of Inflammation, Vol. 2012, 874149, 2012.

Research output: Contribution to journalArticle

Falcone, Colomba ; Buzzi, Maria Paola ; Bozzini, Sara ; Boiocchi, Chiara ; D'Angelo, Angela ; Schirinzi, Sandra ; Esposito, Ciro ; Torreggiani, Massimo ; Choi, Jasmine ; Ochan Kilama, Michael ; Mancia, Giuseppe. / Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment : A substudy of TALENT. In: Mediators of Inflammation. 2012 ; Vol. 2012.
@article{c7ec20fab62c40ed9b5ca01c420d7451,
title = "Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: A substudy of TALENT",
abstract = "Some antihypertensive drugs have also renoprotective and anti-inflammatory properties that go beyond their effect on blood pressure. It has been suggested that microalbuminuria and glomerular filtration rate (GFR) are associated with circulating levels of the soluble form of the receptor, sRAGE (soluble receptor for advanced glycation ends-products). In the present analysis, we used data from the TALENT study to evaluate soluble receptor for advanced glycation end-products (sRAGE) plasma levels in patients with hypertension and high-cardiovascular risk-treated nifedipine and telmisartan in combination. Treatment with nifedipine-telmisartan significantly decreased mean systolic and diastolic ambulatory blood pressure and resulted in a significant increase in sRAGE plasma concentrations after 24 weeks of therapy. We concluded that in hypertensive patients with early-stage renal disease, sRAGE concentrations are not influenced by either microalbuminuria or GFR. Long-term treatment with a combination of nifedipine-telmisartan may have a beneficial effect increasing sRAGE plasma levels, thus exerting an atheroprotective and anti-inflammatory activity.",
author = "Colomba Falcone and Buzzi, {Maria Paola} and Sara Bozzini and Chiara Boiocchi and Angela D'Angelo and Sandra Schirinzi and Ciro Esposito and Massimo Torreggiani and Jasmine Choi and {Ochan Kilama}, Michael and Giuseppe Mancia",
year = "2012",
doi = "10.1155/2012/874149",
language = "English",
volume = "2012",
journal = "Mediators of Inflammation",
issn = "0962-9351",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment

T2 - A substudy of TALENT

AU - Falcone, Colomba

AU - Buzzi, Maria Paola

AU - Bozzini, Sara

AU - Boiocchi, Chiara

AU - D'Angelo, Angela

AU - Schirinzi, Sandra

AU - Esposito, Ciro

AU - Torreggiani, Massimo

AU - Choi, Jasmine

AU - Ochan Kilama, Michael

AU - Mancia, Giuseppe

PY - 2012

Y1 - 2012

N2 - Some antihypertensive drugs have also renoprotective and anti-inflammatory properties that go beyond their effect on blood pressure. It has been suggested that microalbuminuria and glomerular filtration rate (GFR) are associated with circulating levels of the soluble form of the receptor, sRAGE (soluble receptor for advanced glycation ends-products). In the present analysis, we used data from the TALENT study to evaluate soluble receptor for advanced glycation end-products (sRAGE) plasma levels in patients with hypertension and high-cardiovascular risk-treated nifedipine and telmisartan in combination. Treatment with nifedipine-telmisartan significantly decreased mean systolic and diastolic ambulatory blood pressure and resulted in a significant increase in sRAGE plasma concentrations after 24 weeks of therapy. We concluded that in hypertensive patients with early-stage renal disease, sRAGE concentrations are not influenced by either microalbuminuria or GFR. Long-term treatment with a combination of nifedipine-telmisartan may have a beneficial effect increasing sRAGE plasma levels, thus exerting an atheroprotective and anti-inflammatory activity.

AB - Some antihypertensive drugs have also renoprotective and anti-inflammatory properties that go beyond their effect on blood pressure. It has been suggested that microalbuminuria and glomerular filtration rate (GFR) are associated with circulating levels of the soluble form of the receptor, sRAGE (soluble receptor for advanced glycation ends-products). In the present analysis, we used data from the TALENT study to evaluate soluble receptor for advanced glycation end-products (sRAGE) plasma levels in patients with hypertension and high-cardiovascular risk-treated nifedipine and telmisartan in combination. Treatment with nifedipine-telmisartan significantly decreased mean systolic and diastolic ambulatory blood pressure and resulted in a significant increase in sRAGE plasma concentrations after 24 weeks of therapy. We concluded that in hypertensive patients with early-stage renal disease, sRAGE concentrations are not influenced by either microalbuminuria or GFR. Long-term treatment with a combination of nifedipine-telmisartan may have a beneficial effect increasing sRAGE plasma levels, thus exerting an atheroprotective and anti-inflammatory activity.

UR - http://www.scopus.com/inward/record.url?scp=84858114914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858114914&partnerID=8YFLogxK

U2 - 10.1155/2012/874149

DO - 10.1155/2012/874149

M3 - Article

C2 - 22474401

AN - SCOPUS:84858114914

VL - 2012

JO - Mediators of Inflammation

JF - Mediators of Inflammation

SN - 0962-9351

M1 - 874149

ER -